N-acetyl mannosammine as a therapeutic agent
The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
1. A method of treating a condition or disease in a mammal in need thereof comprising
selecting a mammal with the condition or disease; and
administering to the mammal an effective amount of N-acetyl mannosamine or a derivative thereof, wherein the derivative consists of Formula I:
wherein R 1 , R 3 , R 4 , or R 5 is hydrogen, lower alkanoyl, carboxylate or lower alkyl; R 2 is lower alkyl, lower alkanoylalkyl, lower alkyl alkanoyloxy; and the condition or disease is muscular dystrophy, high blood pressure, or diabetes.
2. A method of treating a condition or disease in a mammal in need thereof comprising
selecting a mammal with the condition or disease; and
administering to the mammal a therapeutically effective amount of N-acetyl mannosamine to the mammal, wherein the condition or disease is muscular atrophy, muscular dystrophy, high blood pressure, or diabetes.
3. The method of claim 2 , wherein the therapeutic amount is about 0.1 g to about 50 g N-acetyl mannosamine per day.
4. The method of claim 2 , wherein the therapeutic amount is administered in a unit dosage of about 0.01 g to about 50 g N-acetyl mannosamine per unit dosage.
5. The method of claim 1 , comprising sustained release of the N-acetyl mannosamine or a derivative thereof.
6. The method of claim 1 , comprising topical administration of N-acetyl mannosamine or a derivative thereof.
7. The method of claim 1 , wherein the method reduces hematuria and/or proteinuria in the mammal.
8. A method of reducing proteinuria in a mammal in need thereof comprising:
selecting a mammal with a condition or disease, and
administering to the mammal an effective amount of N-acetyl mannosamine or a derivative thereof, to the mammal, wherein the derivative consists of Formula I:
wherein R 1 , R 3 , R 4 , or R 5 is hydrogen, lower alkanoyl, carboxylate or lower alkyl; R 2 is lower alkyl, lower alkanoylalkyl, lower alkyl alkanoyloxy; and wherein the condition or disease is high blood pressure, diabetes, or diabetic nephropathy, thereby reducing proteinuria in the mammal.
9. The method of claim 8 , comprising administering a therapeutic amount of N-acetyl mannosamine to the mammal.
10. The method of claim 9 , wherein the therapeutic amount is about 0.1 g to about 50 g N-acetyl mannosamine per day.
11. The method of claim 9 , wherein the therapeutic amount is administered in a unit dosage of about 0.01 g to about 50 g N-acetyl mannosamine per unit dosage.
12. The method of claim 8 , comprising sustained release of the N-acetyl mannosamine or a derivative thereof.
13. The method of claim 8 , comprising topical administration of the N-acetyl mannosamine or a derivative thereof.
14. The method of claim 9 , wherein the N-acetyl mannosamine is administered orally to the mammal.
15. The method of claim 9 , wherein the N-acetyl mannosamine is microencapsulated.
16. The method of claim 1 , comprising oral administration of N-acetyl mannosamine or a derivative thereof.